Abstract
Objective: This study aimed to elucidate the role of the IAH1 gene across multiple cancer types. Methods: Using multi-omics data from public databases including TCGA, GTEx, TIMER, and cBioPortal, we analyzed the expression patterns of IAH1 and their correlations with prognostic outcomes, immune cell infiltration, immune checkpoint markers, tumor mutational burden (TMB), microsatellite instability (MSI), response to immunotherapy, and drug sensitivity through bioinformatic tools and R software. Results: IAH1 expression was significantly upregulated in most cancers and associated with adverse prognosis. Elevated IAH1 levels correlated strongly with immune-related gene expression, immune checkpoint levels, TMB, MSI, and immune infiltration. Moreover, IAH1 expression was linked to sensitivity to anticancer drugs and survival outcomes following immune checkpoint inhibitor (ICI) treatment. Conclusions: IAH1 may serve as a promising immunoregulatory target and potential biomarker for diagnosis and prognosis in specific cancers.